Equities Analysts Offer Predictions for Cyclo Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:CYTH)

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Cyclo Therapeutics in a report released on Wednesday, May 1st. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Cyclo Therapeutics’ current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.64) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.47) EPS and FY2027 earnings at ($0.38) EPS.

Cyclo Therapeutics (NASDAQ:CYTH) last released its quarterly earnings data on Monday, March 18th. The company reported ($0.23) earnings per share for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%. The business had revenue of $0.31 million during the quarter.

Separately, Ascendiant Capital Markets began coverage on shares of Cyclo Therapeutics in a report on Monday, April 22nd. They set a “buy” rating and a $2.60 price objective on the stock.

Cyclo Therapeutics Stock Performance

NASDAQ:CYTH opened at $1.51 on Friday. The firm has a 50-day simple moving average of $1.45 and a 200-day simple moving average of $1.47. Cyclo Therapeutics has a one year low of $0.89 and a one year high of $2.57. The firm has a market cap of $43.37 million, a P/E ratio of -1.15 and a beta of -0.18.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund V Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics comprises 80.8% of Founders Fund V Management LLC’s holdings, making the stock its biggest position. Founders Fund V Management LLC owned 2.11% of Cyclo Therapeutics as of its most recent filing with the SEC. 68.55% of the stock is currently owned by hedge funds and other institutional investors.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.